← Browse by Condition
Medical Condition
scleroderma
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2
NCT06991114 Phase 2
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Enrollment
90 pts
Location
United States, Bulga...
Sponsor
Artiva Biotherapeutics, Inc.
NCT07292961
Recruiting
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Enrollment
48 pts
Location
Turkey (Türkiye)
Sponsor
Hacettepe University
NCT04265144
Recruiting
Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre
Enrollment
500 pts
Location
France
Sponsor
University Hospital, Bordeaux
NCT04797286 Phase 2
Recruiting
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Enrollment
30 pts
Location
United States
Sponsor
Johns Hopkins University
NCT01793168
Recruiting
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Enrollment
20,000 pts
Location
United States, Austr...
Sponsor
Sanford Health
NCT03800017
Recruiting
Skeletal Muscle Function in Interstitial Lung Disease
Enrollment
40 pts
Location
Canada
Sponsor
University of British Columbia